# OnCo record nct02786485 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02786485/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02786485", "NCT02786485" ;
  schema:name "Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT"@en ;
  schema:description "A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, withdrawn before enrolling."@en ;
  schema:url <https://onco.cc/trials/nct02786485/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02786485> ;
  onco:status "withdrawn" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/leukaemia/>, <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:drugs <https://onco.cc/drugs/rivogenlecleucel/> ;
  onco:companies <https://onco.cc/companies/bellicum/> .